Current approaches to incorporation of radium-223 in clinical practice.

ABSTRACT:

Background

Treatment options for metastatic castration-resistant prostate cancer (mCRPC) have expanded in recent years and include cytotoxic agents (e.g., docetaxel and cabazitaxel), immunotherapy (e.g., sipuleucel-T), oral hormonal therapies targeting the androgen receptor axis (e.g., enzalutamide and abiraterone), and targeted alpha therapy (e.g., radium-223 dichloride (radium-223)). Although treatment guidelines have been updated to reflect the availability of new agents, it is not easy to apply them in daily clinical practice because recommendations vary depending on patient comorbidities and disease characteristics. Furthermore, therapeutic accessibility, clinical judgment, and experience affect the selection of treatment options.

Methods

In this review, we provide prac

SUBMITTER: Parker C 

PROVIDER: S-EPMC5895600 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature